A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir

[Image: see text] The SARS-CoV-2 pandemic is currently causing an unprecedented global health emergency since its emergence in December 2019. In December 2021, the FDA granted emergency use authorization to nirmatrelvir, a SARS-CoV-2 main protease inhibitor, for treating infected patients. This pept...

Descripción completa

Detalles Bibliográficos
Autores principales: Vankadara, Subramanyam, Dawson, Monique Danielle, Fong, Jia Yi, Oh, Qin Yao, Ang, Qi An, Liu, Boping, Chang, Hong Yun, Koh, Judice, Koh, Xiaoying, Tan, Qian Wen, Joy, Joma, Chia, Cheng San Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331150/
https://www.ncbi.nlm.nih.gov/pubmed/35971455
http://dx.doi.org/10.1021/acsmedchemlett.2c00260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331150/
https://www.ncbi.nlm.nih.gov/pubmed/35971455
http://dx.doi.org/10.1021/acsmedchemlett.2c00260

Ejemplares similares